Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

12.58B

Market cap12.58B

Price-Earnings ratio

16.58

Price-Earnings ratio16.58

Dividend yield

—

Dividend yield—

Average volume

2.32M

Average volume2.32M

High today

$50.01

High today$50.01

Low today

$50.01

Low today$50.01

Open price

$50.09

Open price$50.09

Volume

1.10K

Volume1.10K

52 Week high

$51.63

52 Week high$51.63

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $50.01. The company's market cap stands at 12.58B, with a P/E ratio of 16.58.

On 2026-05-28, Exelixis(EXEL) stock traded between a low of $50.01 and a high of $50.01. Shares are currently priced at $50.01, which is 0.0% above the low and 0.0% below the high.

The Exelixis(EXEL)'s current trading volume is 1.1K, compared to an average daily volume of 2.32M.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $51.63 and a 52-week low of $33.76.

EXEL News

Simply Wall St 9h

Exelixis Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration

Exelixis (EXEL) has put fresh attention on its oncology pipeline after announcing extensive CABOMETYX and zanzalintinib data presentations at the 2026 ASCO meet...

Simply Wall St 2d

Have Exelixis Insiders Been Selling Stock?

We wouldn't blame Exelixis, Inc. ( ) shareholders if they were a little worried about the fact that Patrick Haley, the Executive Vice President of Commercial re...

Nasdaq 5d

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Pe...

Analyst ratings

45%

of 20 ratings

Buy

45%

Hold

45%

Sell

10%

More EXEL News

TipRanks 5d

Top Exelixis Executive Makes Major Move With Fresh Stock Sale

New insider activity at Exelixis ( (EXEL) ) has taken place on May 22, 2026. Start a conversation with TipRanks’ trusted, data-backed investment intelligence...

Simply Wall St 7d

How Investors May Respond To Exelixis Merck MRD+ Colorectal Cancer Trial Collaboration

Earlier in May 2026, Exelixis announced a clinical development collaboration with Merck, under which Exelixis will sponsor the planned phase 3 STELLAR-316 trial...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.